BS
ACAD icon

Boenning & Scattergood’s Acadia Pharmaceuticals ACAD Stock Holding History

Boenning & Scattergood’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.29M Buy
53,475
+23,215
+77% +$363K 0.21% 122
2022
Q3 		$495K Sell
30,260
-200
-0.7% -$3.24K 0.1% 224
2022
Q2 		$429K Sell
30,460
-23,015
-43% -$430K 0.08% 248
2022
Q1 		$1.29M Hold
53,475
– – 0.21% 122
2021
Q4 		$1.25M Sell
53,475
-400
-0.7% -$8.04K 0.2% 126
2021
Q3 		$894K Sell
53,875
-5,000
-8% -$96.4K 0.16% 155
2021
Q2 		$1.44M Buy
58,875
+25,000
+74% +$564K 0.25% 108
2021
Q1 		$874K Hold
33,875
– – 0.17% 149
2020
Q4 		$1.81M Hold
33,875
– – 0.38% 68
2020
Q3 		$1.4M Buy
33,875
+400
+1% +$17.3K 0.34% 78
2020
Q2 		$1.62M Hold
33,475
– – 0.43% 57
2020
Q1 		$1.41M Buy
33,475
+3,875
+13% +$160K 0.49% 52
2019
Q4 		$1.27M Buy
29,600
+3,000
+11% +$131K 0.33% 76
2019
Q3 		$957K Hold
26,600
– – 0.28% 104
2019
Q2 		$711K Sell
26,600
-25,050
-48% -$640K 0.21% 127
2019
Q1 		$1.39M Buy
51,650
+2,350
+5% +$54.9K 0.42% 68
2018
Q4 		$797K Buy
49,300
+3,000
+6% +$58.3K 0.28% 104
2018
Q3 		$961K Sell
46,300
-400
-0.9% -$6.29K 0.31% 92
2018
Q2 		$713K Buy
+46,700
New +$833K 0.23% 125

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Boenning & Scattergood's ACAD Position: Q4 2022 in Review

Boenning & Scattergood increased its Acadia Pharmaceuticals (ACAD) stake by 77% in Q4 2022, buying an estimated $363K and bringing the position to 53,475 shares worth $1.29M. The position accounts for 0.21% of the portfolio, ranked #122.

Boenning & Scattergood first reported a position in ACAD in Q2 2018 and has held it in 19 quarters since. The position peaked at $1.81M in Q4 2020. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • Boenning & Scattergood held 53,475 shares of Acadia Pharmaceuticals worth $1.29M as of Q4 2022.
  • Boenning & Scattergood bought 23,215 Acadia Pharmaceuticals shares in Q4 2022, an estimated $363K.
  • Acadia Pharmaceuticals made up 0.21% of Boenning & Scattergood's portfolio in Q4 2022, its #122 holding.
  • Boenning & Scattergood first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • Boenning & Scattergood's Acadia Pharmaceuticals position peaked at $1.81M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.